Our class I exempt medical device, The Mitra® microsampler, is based on Volumetric Absorptive Microsampling (VAMS™) technology. It facilitates convenient specimen collection and transportation of blood and other biological fluids to improve animal and patient welfare, reduce laboratory costs, and enable new value-based, patient-centered models of care.
A chat over the limitations of Dried Blood Spot (DBS) cards between Dr. James Rudge (Phenomenex) and Dr. Neil Spooner (GlaxoSmithKline) reveals the market potential for a next generation dried blood microsampling technology.
10 µL devices based on VAMS™ technology are thoroughly tested by five leading pharmaceutical organizations, validating that they collect fixed volumes of blood while eliminating the volumetric hematocrit bias associated with DBS cards. Neoteryx is born!
As a CE-IVD registered device, Neoteryx is prepared to introduce the in vitro diagnostic European market to next generation dried blood collection and transportation.
Neoteryx expands into the United Kingdom to better serve its growing European customer base.
The Mitra® microsampler is listed as an FDA Class 1 exempt medical device.
Responding to customer demand for a higher-volume specimen, Neoteryx releases 20 µL Mitra® microsamplers.
Manufacturing expands into a new building - Neo 2 - to better accommodate the growing need to manufacture more of this technology.
Mitra® devices gain wider acceptance through projects by some of the biggest names health, research, and medicine - Quest Diagnostics, Charles River Labs, Exagen Diagnostics, and Duke University, to name a few.
With the release of the 30 µL tips, users of Mitra® devices now collect more blood. This facilitates detection of analytes with low blood concentrations and multiplex analyses from one sampler tip.
Increasing awareness of the VAMS™ advantage leads to a host of groundbreaking research. including breakthroughs in measuring HbA1c in diabetic patients, advances in therapeutic drug monitoring and clinical trials, and opening new care pathways in remote patient monitoring.
To further meet the needs of the European market, Neoteryx opens Neoteryx B.V. in Maastricht, the Netherlands.
At only five years old, VAMS™ rides a wave of commercial and academic interest to rack up its 65th publication.
Increased use of microsampling in patient monitoring drives exploration of new health and wellness applications, with a focus on drug and alcohol testing.
